期刊文献+

2型糖尿病患者的颈动脉内膜-中膜厚度 被引量:4

Carotid infima-media thickness in patients with type 2 diabetes mellitus
原文传递
导出
摘要 糖尿病相关大血管疾病是2型糖尿病的主要威胁,其主要病理学机制是动脉粥样硬化。利用高分辨率超声技术检测颈动脉内膜一中膜厚度(carotid intima-media thickness,CIMT)作为亚临床动脉粥样硬化的替代指标,业已证实其为心脑血管病的强烈预测因素。文章将着重阐述2型糖尿病患者CIMT相关危险因素的最新研究进展。 Diabetes associated large vascular disease is a major threat to type 2 diabetes meUitus, its main pathological mechanism is atherosclerosis. Carotid intima-media thickness (CIMT) detected using high resolution ultrasound technique can be used as an alternative indicator of subclinical atherosclerosis. It has been confirmed that it is a strong predictor of cardio-cerebrovascular diseases. This article focuses on the latest research progress of the CIMT-associated risk factors in patients with type 2 diabetes mellitus.
出处 《国际脑血管病杂志》 北大核心 2014年第10期773-777,共5页 International Journal of Cerebrovascular Diseases
关键词 糖尿病 2型 颈动脉疾病 颈动脉内膜-中膜厚度 糖尿病血管病变 危险因素 Diabetes Mellitus, Type 2 Carotid Artery Diseases Carotid Intima-Media Thickness Diabetic Angiopathies Risk Factors
  • 相关文献

参考文献4

二级参考文献39

  • 1张翼飞,洪洁,顾卫琼,孙首悦,唐金凤,江凌,戴蒙,赵咏桔,宁光.血清游离脂肪酸水平在不同体重指数及糖耐量个体中与胰岛素敏感性及相关指标的关系[J].中华内科杂志,2003,42(11):793-796. 被引量:16
  • 2Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., Wright, A.D., Turner, R.C., Holman, R.R., 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321(7258):412-419. [doi:10.1136/bmj.321.7258. 412].
  • 3Aronson, D., 2008. Hyperglycemia and the Pathobiology of Diabetic Complications. In: Fisman, E.Z., Tenenbaum, A. (Eds.), Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Adv. Cardiol. Basel, Karger, vol.45, p.1-16. [doi:10.1159/000115118].
  • 4Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., Thomason, M.J., Mackness, M.I., Charlton-Menys, V., Fuller, J.H., 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364(9435): 685-696. [doi:10.1016/S0140-6736(04)16895-5].
  • 5Fruchart, J.C., Sacks, F., Hermans, M.P., Assmann, G., Brown, W.V., Ceska, R., Chapman, M.J., Dodson, P.M., Fioretto, P., Ginsberg, H.N., et al., 2008. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol., 102(10 Suppl.):1K-34K. [doi:10.1016/j.amjcard. 2008.10.002].
  • 6Gde, P., Lund-Andersen, H., Parving, H.H., Pedersen, O., 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med., 358(6):580-591. [doi:10.1056/NEJMoa0706245].
  • 7Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, W., Smith, S.C.Jr., Sowers, J.R., 1999. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 100(10):1134-1146. [doi: 10.1161/01.CIR.100.10.1134].
  • 8Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B.Jr., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C.Jr., Stone, N.J., 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Am. Coll. Cardiol., 44(3):720-732. [doi:10.1016/j.jacc.2004.07.001].
  • 9Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 359(15): 1577-1589. [doi:10.1056/NEJMoa0806470].
  • 10Kanter, J.E., Johansson, F., LeBoeuf, R.C., Bornfeldt, K.E., 2007. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circul. Res., 100(6):769-781. [doi:10. 1161/01.RES.0000259589.34348.74].

共引文献58

同被引文献37

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部